Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Savaria today and set a price target of C$24.00. The company’s shares opened today at C$20.87. Take advantage of TipRanks Premium at ...

What Happened? Shares of medical device company Artivion (NYSE:AORT) jumped 20.3% in the morning session after it reported ...

Microchip Technology (NASDAQ:MCHP) was down 4% during Friday market action following second quarter results that surpassed ...

Accenture Plc (NYSE: ACN) is one of the best depressed stocks to buy in 2025. On July 11, analysts at Stifel reiterated a ...

An Osaic Wealth financial advisor recommended that one customer, an 84-year-old widow, invest in the fund in May, days before ...

Fintel reports that on August 7, 2025, Stifel upgraded their outlook for ESAB (NYSE:ESAB) from Hold to Buy. Analyst Price ...

D-Wave Quantum Inc. (NYSE:QBTS) is one of the Best Performing Quantum Computing Stocks So Far in 2025. On August 5, Stifel ...

Rocket Lab shares dipped 1.41% to $43.88 despite a flawless Electron mission, Stifel's buy rating (raising its target to $55) ...

Rapper Jeezy brings his "TM:101" 20th anniversary tour to the Stifel Theatre for a black-tie performance with the Color of ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $126.25, a high estimate of ...